Immune System News and Research

RSS

HIV infection in mothers reduces disease resistance in babies: Study

New research suggests that babies whose mothers have HIV, but are not HIV-infected themselves, are born with lower levels of specific proteins in their blood called antibodies, which fight infection, compared with babies not exposed to HIV.

13 Feb 2011

Protective immunity against HIV can be achieved without presence of virus neutralizing antibodies in the blood

New research shows that protective immunity against HIV can be achieved without the presence of virus neutralizing antibodies in the blood. The study, published by Cell Press in the February issue of the journal Immunity, demonstrates that a vaccine which stimulates production of specific anti-HIV antibodies in the vaginal tissue was sufficient to protect monkeys from exposure to live virus.

11 Feb 2011

Vaccinating through salivary glands may provide protection against wide range of diseases

If you don't like shots or needles, you're in luck. New research published online in The FASEB Journal gives the development of new oral vaccinations a shot in the arm thanks to discoveries involving the salivary glands of mice. In addition, this research report also offers a tantalizing glimpse of vaccines that could prevent infection at mucosal surfaces, even if direct injections into the body fail to cause immunity. This technique may be effective for a wide range of diseases from influenza to cholera.

11 Feb 2011

Blocking interleukin 15 may help restore oral tolerance to gluten

Blocking a factor that can activate the human immune response against intestinal bacteria or certain foods could prevent the development of celiac disease in those most at risk, researchers report in the journal Nature.

11 Feb 2011

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."

11 Feb 2011

RF-induced heat therapy could help treat common parasitic skin infection

Scientists are hoping that heat therapy could eventually replace a complex drug regimen as the first-line treatment of a parasitic skin infection common in tropical and subtropical regions of the world.

11 Feb 2011

Richard J. Fasenmyer Foundation awards $3M to Cleveland physicians for AIDS research

A three-year, $3 million gift from the Richard J. Fasenmyer Foundation will fund research by a pair of Cleveland physicians into HIV and the body's response in autoimmune diseases.

11 Feb 2011

Viral infection of Leishmania leads to increased pathogenicity

A parasite and a virus may be teaming up in a way that increases the parasite's ability to harm humans, scientists at the University of Lausanne in Switzerland and Washington University School of Medicine in St. Louis report this week in Science.

11 Feb 2011

Study finds too low drug concentrations used for treatment of children with TB

The realization of medically treating different children uniquely may start with one of the deadliest diseases in existence: tuberculosis.

11 Feb 2011

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 1b clinical study of PRM-151 to explore the safety, tolerability, pharmacokinetics, and phamacodynamics of PRM-151 in the treatment of patients with idiopathic pulmonary fibrosis.

11 Feb 2011

Avian flu vaccine stockpiled in 2004 still useful

A stockpiled vaccine designed to fight a strain of avian flu that circulated in 2004 can be combined with a vaccine that matches the current strain of bird flu to protect against a potential pandemic, researchers from Saint Louis University's Center for Vaccine Development have found.

10 Feb 2011

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

Cell Medica, a leading UK cellular therapeutics company that develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, announces today that the first patient has been treated in the CMV~ACE/ASPECT trial at University College Hospital London.

10 Feb 2011

NIAID doctor receives Will Rogers Institute's award for outstanding contributions to lung research

The Will Rogers Institute's annual prize for outstanding contributions to lung research has been awarded to Dr. Anthony Fauci. The $50,000 award was created to honor individuals for extraordinary work leading to advancements in treatment for lung diseases. He is the fourth recipient of the prestigious prize from the Will Rogers Institute.

10 Feb 2011

Liquidia to explore PRINT particle technology with PATH Malaria Vaccine Initiative

Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.

10 Feb 2011

IDF commends Illinois advisory committee for unanimous vote to recommend SCID Newborn Screening

The Illinois Genetic and Metabolic Diseases Advisory Committee voted unanimously to recommend that the Department of Health screen all newborns for Severe Combined Immune Deficiency (SCID) - commonly known as bubble boy disease.

9 Feb 2011

GeoVax opens second HIV clinical trial site at Alabama Vaccine Research Clinic

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a second clinical trial site at the Alabama Vaccine Research Clinic (AVRC) of the University of Alabama at Birmingham (UAB) to expand the company's HIV therapeutic vaccine trial.

9 Feb 2011

Single molecule imaging movies of living cell membranes clarify enigma surrounding receptor molecule behaviors

Unprecedented single molecule imaging movies of living cell membranes, taken by a research team based at Kyoto University and the University of New Mexico, have clarified a decades-old enigma surrounding receptor molecule behaviors. The results, appearing in the latest issue of the Journal of Cell Biology, promise to open the door to new possibilities for drug development.

9 Feb 2011

Topical cream used to treat skin diseases activates two distinct neuronal signaling pathways

Scratching deep beneath the surface, a team of researchers from the University of California, San Diego School of Medicine and three South Korean institutions have identified two distinct neuronal signaling pathways activated by a topical cream used to treat a variety of skin diseases. One pathway produces the therapeutic benefit; the other induces severe itching as a side effect.

9 Feb 2011

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales.

9 Feb 2011

Updating approach to pharmacy benefits will help Florida Medicaid save $462 million

"Governor Scott is taking important steps to reduce wasteful spending in Medicaid, which is a big problem when it comes to pharmacy benefits. Because of its old-school 'fee-for-service' approach, Florida Medicaid pays drugstores much more than either Medicare or the commercial market pays them. Over the next decade, Florida could save $462 million - without cutting benefits, eligibility or payments to doctor and hospitals - simply by updating its approach to pharmacy benefits."

9 Feb 2011

Immune System News and Research

HIV infection in mothers reduces disease resistance in babies: Study

Protective immunity against HIV can be achieved without presence of virus neutralizing antibodies in the blood

Vaccinating through salivary glands may provide protection against wide range of diseases

Blocking interleukin 15 may help restore oral tolerance to gluten

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

RF-induced heat therapy could help treat common parasitic skin infection

Richard J. Fasenmyer Foundation awards $3M to Cleveland physicians for AIDS research

Viral infection of Leishmania leads to increased pathogenicity

Study finds too low drug concentrations used for treatment of children with TB

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Avian flu vaccine stockpiled in 2004 still useful

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

NIAID doctor receives Will Rogers Institute's award for outstanding contributions to lung research

Liquidia to explore PRINT particle technology with PATH Malaria Vaccine Initiative

IDF commends Illinois advisory committee for unanimous vote to recommend SCID Newborn Screening

GeoVax opens second HIV clinical trial site at Alabama Vaccine Research Clinic

Single molecule imaging movies of living cell membranes clarify enigma surrounding receptor molecule behaviors

Topical cream used to treat skin diseases activates two distinct neuronal signaling pathways

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

Updating approach to pharmacy benefits will help Florida Medicaid save $462 million

Immunology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News